– UK, London – Concepta plc (AIM:CPT), the UK healthcare company targeting the personalised mobile health market with a primary focus on women’s fertility, is pleased to announce the appointment of Neil Mesher as a Non-Executive Director, with immediate effect. This appointment further bolsters the Concepta management team’s commercial healthcare credentials ahead of the launch of its myLotus fertility product into China in 2017 and Europe thereafter.
Neil has more than 25 years of global experience within the healthcare and consumer electronics industries. He is currently CEO of Philips for the UK and Ireland and is on the Board of the Association of British Healthcare Industries (ABHI), from which he led the industry’s response to the NHS’s “5 Year Forward View”, assessing opportunities for greater integration between industry and the healthcare system. Neil is also a member of the Government’s Life Science Industrial Strategy Board, representing the interests of the medical technology sector with other senior leaders from across healthcare.
In line with the Company’s new Non-Executive Director appointment, Concepta also announces that Neil Herbert has stepped down from his position as non-Executive Director with immediate effect. Neil was Chairman of Frontier Resources International Plc and from February 2016 remained as a Non-executive Director during the Concepta RTO. The Board wish to thank him for his contribution with the initial transition of Concepta plc.
Erik Henau, Chief Executive of Concepta, commented: “I am delighted to welcome Neil to the Board as a Non-Executive Director. His experience and insight within the healthcare industry and consumer electronics in particular will complement our existing expertise in diagnostics and will also supplement our efforts to diversify our offering to improve users’ ability to manage a range of conditions beyond our current core fertility business.”
Neil Mesher, Non-Executive Director of Concepta commented: “SME’s and start-ups consistently show high levels of innovation and growth, but are often under-represented in strategic initiatives to bring about improvements in the healthcare system and in turn patient outcomes. Concepta is a tremendously interesting business with the potential to bring such innovation and I look forward to adding value at company level and at a much wider country level.”
About Concepta Plc:
Concepta plc is a pioneering UK healthcare company that has developed a proprietary platform and products targeted at the personalised mobile health market with a primary focus on women’s fertility and specifically unexplained infertility*.
Founded in 2013, Concepta has developed a revolutionary flagship product ‘myLotus’ for home self-testing that helps women with unexplained infertility to conceive.
myLotus is the only consumer product which allows both quantitative and qualitative measurements of a woman’s personal hCG and LH hormone levels in an easy to use home test to facilitate higher conception rates and early diagnosis of any fertility problems. Competitor products currently only allow qualitative measurement and are based on the ‘average woman’.
Concepta has a defined route to market for its new ‘myLotus’ product with Regulatory approvals for launch in China in place for H1 2017 and CE-Marking for UK and Europe to follow later in 2017, where the revenue potential of the Chinese and EU infertility market is worth c.£600m per annum for the company.
For more information : http://www.conceptaplc.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.